Lentiviral-vector-mediated expression of murine IL-1 receptor antagonist or IL-10 reduces the severity of endotoxin-induced uveitis

Gene Therapy

Volumn 15, Issue 22, 2008, Pages 1478-1488

  Trittibach, P ^a,b   Barker, S E ^a   Broderick, C A ^a   Natkunarajah, M ^a   Duran, Y ^a   Robbie, S J ^a   Bainbridge, J W B ^a   Smith, A J ^a   Sarra, G M ^b   Dick, A D ^c   Ali, R R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DNA; ENDOTOXIN; FLUORESCEIN; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; LENTIVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; ARTICLE; C57BL 6 MOUSE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORNEA ENDOTHELIUM; FEMALE; IMMUNOMODULATION; IN VIVO STUDY; INFLAMMATORY CELL; IRIS; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRABECULAR MESHWORK; TRANSGENE; UVEITIS; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; FEMALE; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HIV-1; HUMANS; INJECTIONS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; TRANSDUCTION, GENETIC; TRANSGENES; UVEA; UVEITIS;

HUMAN IMMUNODEFICIENCY VIRUS 1; MURINAE; MUS;

EID: 55549121559     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.109     Document Type: Article

References (55)

1. Reeves SW, Sloan FA, Lee PP, Jaffe GJ. Uveitis in the elderly: epidemiological data from the national long-term care survey medicare cohort. Ophthalmology 2006, 113: 307
2. Edelsten C, Reddy MA, Stanford MR, Graham EM. Visual loss associated with pediatric uveitis in English primary and referral centers. Am J Ophthalmol 2003; 135: 676-680.
3. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 2004; 111: 491-500.
4. Imrie FR, Dick AD. Nonsteroidal drugs for the treatment of noninfectious posterior and intermediate uveitis. Curr Opin Ophthalmol 2007; 18: 212-219.
5. Broderick CA, Smith AJ, Balaggan KS, Georgiadis A, Buch PK, Trittibach PC et al. Local administration of an adeno-associated viral vector expressing IL-10 reduces monocyte infiltration and subsequent photoreceptor damage during experimental. autoimmune uveitis. Mol Ther 2005; 12: 369-373.
6. Robertson M, Liversidge J, Forrester JV, Dick AD. Neutralizing tumor necrosis factor-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2003; 44: 3034-3041.
7. Tynjala P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007; 66: 548-550.
8. Smith JR, Verwaerde C, Rolling F, Naud MC, Delanoye A, Thillaye-Goldenberg B et al. Tetracycline-inducible viral interleukin-10 intraocular gene transfer, using adeno-associated virus in experimental autoinumme uveoretinitis. Hum Gene Ther 2005; 16: 1037-1046.
9. Rosenbaum JT, McDevitt HO, Guss RB, Egbert PR. Endotoxin-induced uveitis in rats as a model for human disease. Nature 1980; 286: 611-613.
10. Forrester JV, Worgul BV, Merriam Jr GR. Endotoxin-induced uveitis in the rat. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1980; 213 221-233.
11. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994; 12: 141-179.
12. Baeuerle PA, Baltimore D. NF-kappa B: Ten years after. Cell 1996; 87: 13-20.
13. de Vos AF, Klaren VN, Kijlstra A. Expression of multiple cytokines and IL-1RA in the uvea and retina during endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci 1994; 35: 3873-3883.
14. Planck SR, Huang XN, Robertson JE, Rosenbaum JT. Cytokine mRNA levels in rat ocular tissues after systemic endotoxin treatment. Invest Ophthalmol Vis Sci 1994; 35: 924-930.
15. Shen DF, Buggage RR, Eng HC, Chan CC. Cytokine gene expression in different strains of mice with endotoxin-induced uveitis (EIU). Ocul Immunol Inflamm 2000; 8: 221-225.
16. Tuaillon N, Shen DF, Berger RB, Lu B, Rollins BJ, Chan CC. MCP-1 expression in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 2002; 43: 1493-1498.
17. Jacquemin E, De Kozak Y, Thillaye B, Courtois Y, Goureau O. Expression of inducible nitric oxide synthase in the eye from endotoxin-induced uveitis rats. Invest Ophthalmol Vis Sci 1996; 37: 1187-1196.
18. Bellot JL, Palmero M, Garcia-Cabanes C, Espi R, Hariton C, Orts A. Additive effect of nitric oxide and prostaglandin-E2 synthesis inhibitors in endotoxin-induced uveitis in the rabbit. Inflamm Res 1996; 45: 203-208.
19. Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 2002; 13: 323-340.
20. Hill N, Sarvetnick N. Cytokines: Promoters and dampeners of autoimmunity. Curr Opin Immunol 2002; 14: 791-797.
21. Riley JK, Takeda K, Akira S, Schreiber RD. Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. J Biol Chem 1999; 274: 16513-16521.
22. Hayashi S, Guex-Crosier Y, Delvaux A, Velu T, Roberge FG. Interleukin 10 inhibits inflammatory cells infiltration in endotoxin-induced uveitis. Graefes Arch Clin Exp Ophthalmol 1996; 234: 633-636.
23. Bainbridge JW, Stephens C, Parsley K, Demaison C, Halfyard A, Thrasher AJ et al. In vivo gene transfer to the mouse eye using an HIV-based lentiviral vector; efficient long-term transduction of corneal endothelium and retinal pigment epithelium. Gene Therapy 2001; 8: 1665-1668.
24. Demaison C, Brouns G, Blundell MP, Goldman JP, Levinsky RJ, Grez M et al. A defined window for efficient gene marking of severe combined immunodeficient-repopulating cells using a gibbon ape leukemia virus-pseudotyped retroviral vector. Hum Gene Ther 2000; 11: 91-100.
25. Tschernutter M, Schlichtenbrede FC, Howe S, Balaggan KS, Munro PM, Bainbridge JW et al. Long-term preservation of retinal function in the RCS rat model of retinitis pigmentosa following lentivirus-mediated gene therapy. Gene Therapy 2005; 12: 694-701.
26. Yanez-Munoz RJ, Balaggan KS, MacNeil A, Howe SJ, Schmidt M, Smith AJ et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 2006; 12: 348-353.
27. Qin L, Ding Y, Pahud DR, Chang E, Imperiale MJ, Bromberg JS. Promoter attenuation in gene therapy: Interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression. Hum Gene Ther 1997; 8: 2019-2029.
28. Cominelli F, Nast CC, Clark BD, Schindler R, Lierena R, Eysselein VE et al. Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 1990; 86: 972-980.
29. Cominelli F, Nast CC, Duchini A, Lee M. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology 1992; 103: 65-71.
30. Thomas TK, Will PC, Srivastava A, Wilson CL, Harbison M, Little J et al. Evaluation of an interleukin-1 receptor antagonist in the rat acetic acid-induced colitis model. Agents Actions 1991; 34: 187-190.
31. McCall RD, Haskill S, Zimmermann EM, Lund PK, Thompson RC, Sartor RB. Tissue interleukin 1 and interleukin-1 receptor antagonist expression in enterocolitis in resistant and susceptible rats. Gastroenterology 1994; 106: 960-972.
32. Lim WK, Fujimoto C, Ursea R, Mahesh SP, Silver P, Chan CC et al. Suppression of immune-mediated ocular inflammation in mice by interleukin 1 receptor antagonist administration. Arch Ophthalmol 2005; 123: 957-963.
33. Teoh SC, Sharma S, Hogan A, Lee R, Ramanan AV, Dick AD. Tailoring biological treatment: Anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br J Ophthalmol 2007; 91: 263-264.
34. Grool TA, van Dullemen H, Meenan J, Koster F, ten. Kate FJ, Lebeaut A et al. Anti-inflammatory effect of interleukin-10 in rabbit immune complex-induced colitis. Scand J Gastroenterol 1998; 33: 754-758.
35. Apparailly F, Verwaerde C, Jacquet C, Auriault C, Sany J, Jorgensen C. Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis. J Immunol 1998; 160: 5213-5220.
36. Fang IM, Lin CP, Yang CH, Chiang BL, Yang CM, Chau LY et al. Inhibition of experimental autoimmune anterior uveitis by adenovirus-mediated transfer of the interleukin-10 gene. J Ocul Pharmacol Ther. 2005; 21: 420-428.
37. De Kozak Y, Thillaye-Goldenberg B, Naud MC, Da Costa AV, Auriault C, Verwaerde C. Inhibition of experimental autoimmune uveoretinitis by systemic and subconjunctival adenovirus-mediated transfer of the viral IL-10 gene. Clin Exp Immunol 2002; 130: 212-223.
38. Makarov SS, Olsen JC, Johnston WN, Anderle SY, Brown RR, Baldwin Jr AS et al. Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. Proc Natl Acad Sci USA 1996; 93: 402-406.
39. Pan RY, Chen SL, Xiao X, Liu DW, Peng HJ, Tsao YP. Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist. Arthritis Rheum 2000; 43: 289-297.
40. Huhn RD, Radwanski E, O'Connell SM, Sturgill MG, Clarke L, Cody RP et al. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood 1996; 87: 699-705.
41. Gouze JN, Gouze E, Palmer GD, Liew VS, Pascher A, Betz OB et al. A comparative study of the inhibitory effects of interleukin-1 receptor antagonist following administration as a recombinant protein or by gene transfer. Arthritis Res Ther 2003, 5: R301-R309.
42. Barbara G, Xing Z, Hogaboam CM, Gauldie J, Collins SM. Interleukin 10 gene transfer prevents experimental colitis in rats. Gut 2000; 46: 344-349.
43. Fukumoto T, Matsukawa A, Ohkawara S, Takagi K, Yoshinaga, M. Administration of neutralizing antibody against rabbit IL-1 receptor antagonist exacerbates lipopolysaccharide-induced arthritis in rabbits. Inflamm Res 1996; 45: 479-485.
44. Seely AJ, Pascual JL, Christou NV. Science review: Cell membrane expression (connectivity) regulates neutrophil delivery, function and clearance. Crit Care 2003; 7: 291-307.
45. Ikeda M, Ikeda U, Shimada. K, Minota S, Kano S. Regulation of ICAM-1 expression by inflammatory cytokines in rat mesangial cells. Cytokine 1996; 8: 109-114.
46. Dinarello CA. The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 2002; 20: S1-13.
47. Becker MD, Garman K, Whitcup SM, Planck SR, Rosenbaum JT. Inhibition of leukocyte sticking and infiltration, but not rolling, by antibodies to ICAM-1. and LFA-1 in munne endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 2001; 42: 2563-2566.
48. Whitcup SM, DeBarge LR, Rosen H, Nussenblatt RB,. Chan CC. Monoclonal antibody against CD11b/CD18 inhibits endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 1993, 34: 673-681.
49. Koizumi K, Poulaki V, Doehmen S, Welsandt G, Radetzky S, Lappas A et al. Contribution of TNF-alpha to leukocyte adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo. Invest Ophthalmol Vis Sci 2003; 44: 2184-2191.
50. Yang GY, Mao Y, Zhou LF, Gong C, Ge HL, Betz AL. Expression of intercellular adhesion molecule 1 (ICAM-1) is reduced in permanent focal cerebral ischemic mouse brain using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist. Brain Res Mol Brain Res 1999; 65: 143-150.
51. Sarra GM, Stephens C, Schlichtenbrede FC, Bainbridge JW, Thrasher AJ, Luthert PJ et al. Kinetics of transgene expression in mouse retina following sub-retinal injection of recombinant adeno-associated virus. Vision Res 2002; 42: 541-549.
52. Lai YK, Shen WY, Brankov M, Lai CM, Constable IJ, Rakoczy PE. Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Therapy 2002; 9: 804-813.
53. Abordo-Adesida E, Follenzi A, Barcia C, Sciascia S, Castro MG, Naldini L et al. Stability of Ientiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses. Hum Gene Ther 2005; 16: 741-751.
54. Muhaya M, Calder VL, Towler HM, Jolly G, McLauchlan M, Lightman S. Characterization of phenotype and cytokine profiles of T cell lines derived from vitreous humour in ocular inflammation in man. Clin Exp Immunol 1999; 116: 410-414.
55. Symons JA, Dickens EM, Di Giovine F, Duff GW. Measurement of Interleukin-1 activity In: Clemens MJ, Morris AG, Gearing AJH (eds), Lymphokines and interferons, a practical approach. IRL Press: Oxford, UK, 1987, pp 270-272.